A hemophilia patient hero at zero, BioMarin to seek FDA OK for gene therapy. But will the effect last?
May 28, 2019 at 17:35 PM EDT
BioMarin's gene therapy for hemophilia A dropped potentially life-threatening bleeding events from more than a dozen to zero.
